Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loosened Lip Balm Labeling Allowed By Optional Changes In FDA Rule

This article was originally published in The Tan Sheet

Executive Summary

Lip balms sold in small packages do not have to include label warnings to consult doctors if users' conditions do not clear up in seven days, according to an FDA final rule published Feb. 1 in the Federal Register

You may also be interested in...



Industry Groups Shine Light On “Helps Prevent” Claim In Sunscreen Comments

Sunscreen labeling that claims the product "helps prevent" premature skin aging, cancer and other damage does not suggest sunscreen alone protects against these conditions, but in fact informs consumers that "complementary measures" are needed for adequate protection, according to trade groups' comments on FDA's proposal to amend the sunscreen final monograph

Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity

FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")

Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations

The OTC Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel